Press Release Details

THOUSAND OAKS, Calif., Jan. 13-- Amgen Inc. (Nasdaq: AMGN), the world's largest biotechnology company, today announced that David J. Scott has been named senior vice president, general counsel, secretary and a member of the company's executive committee. In this role, Scott will assume responsibility for Amgen's law organization and oversee development of legal strategies to protect Amgen's intellectual property and maximize its opportunities to market products and serve patients. Scott will join Amgen in February.

Scott's professional and legal career spans more than 25 years and includes experience both in the United States and the United Kingdom. Prior to joining Amgen, Scott served as senior vice president, general counsel and secretary for Medtronic Inc. since 1999, where he oversaw legal, corporate development, government affairs, public relations, regulatory affairs and risk management. Previously, he was general counsel of United Distillers & Vintners in London and senior vice president and general counsel for International Distillers & Vintners (IDV), also in London. Scott also held U.S.-based positions with RJR Nabisco, Inc. and Grand Metropolitan plc and worked as a lawyer in private practice. He holds a J.D. from Cornell Law School and a bachelor's degree from St. Lawrence University.

"David is a seasoned executive with a diverse background and demonstrated record of accomplishment in legal, government and regulatory affairs and corporate development work," said Amgen's Chairman and Chief Executive Officer Kevin Sharer. "His experience and counsel will lead us strategically as Amgen continues to evolve as a global company."

About Amgen

Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.

     CONTACT:   Amgen, Thousand Oaks
                Media, (805) 447-4587
                Investors, (805) 447-1060

An electronic version of this news release may be accessed via our Web site at www.amgen.com . Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Media section of the Web site.

CONTACT:  Amgen, Thousand Oaks, media, +1-805-447-4587, or investors,
+1-805-447-1060
   Web site:  http://www.amgen.com